Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: Jim H who wrote (1098)	12/4/1999 1:18:00 PM
From: scaram(o)uche	Respond to of 4974

Jim: I don't know of any apart from the H&Q thing. The trouble with that one has been the very uneven picks. However, the discount to NAV always makes it tempting. Maybe we should take another look at the current portfolio? The funds stink, but at least two well-known portfolio managers are now following our picks and portfolios, and maybe some of them will get better. We need to get these new funds, Rydex et al., that have spilled out of the inut experience onboard. They obviously just came out with a portfolio of the usual suspects. If we could get them to extend that entrepreneurial spirit to biotech, maybe we'd finally have a fund manager with both brains and guts. The sector as a whole, IMO, has been hurt by the lame fund managers that had control of liquidity when liquidity was at its low. There have been no good fund managers, not even any competent ones, in biotech. The new manager at Fidelity shows promise. Rant off, back to your question..... seems like Suzman fodder to me. The continuing kudos for my performance..... I've done very well. My primary pick in '98 was ARQL, and my only stated '99 target was GLIA at $60. Thus, I'm pretty good at recognizing the picks of friends and collaborators to make up for my own mistakes. Have a good weekend, all! Rick